8-KOther Events

BIOGEN INC. 8-K Report (Feb 13, 2004)

Filed February 13, 2004For Securities:BIIB

Summary

Biogen Idec Inc. (now Biogen Inc.) filed an 8-K on February 13, 2004, to furnish a press release dated February 11, 2004. This press release provides "pro forma" financial results for the full quarter and full year, presenting revenues as if the merger between the former Biogen, Inc. and Idec Pharmaceuticals had occurred at the beginning of the reported periods. These pro forma figures are non-GAAP measures used by management to assess operational performance and trends, and are provided to investors for a more comprehensive understanding of the company's comparative operating performance and future prospects. The primary focus of this filing is to offer a combined financial view post-merger, allowing investors to better evaluate the consolidated entity's revenue generation and operational trajectory without the complexities of partial-period consolidation. While not a formal earnings release, it serves to bridge financial reporting for the recently combined entity.

Key Highlights

  • 1The 8-K filing on February 13, 2004, furnishes a press release dated February 11, 2004, from Biogen Idec Inc.
  • 2The press release presents "pro forma" full quarter and full year revenues, reflecting the combined entity as if the merger occurred earlier.
  • 3These pro forma figures are non-GAAP financial measures.
  • 4Management uses these non-GAAP measures to monitor and evaluate ongoing operating results and trends.
  • 5The company believes these measures offer useful information to investors for understanding comparative operating performance and future prospects.
  • 6The filing aims to provide a consolidated financial perspective for the recently merged company.
  • 7The information is furnished under Item 12 and is not deemed "filed" for certain SEC liability purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to furnish a press release that provides "pro forma" financial results. These results present the combined revenues of Biogen and Idec as if their merger had taken place at the beginning of the reporting periods, allowing for a more consistent view of the combined company's performance.

No, the "pro forma" revenues are explicitly stated as non-GAAP financial measures. While management uses them to assess performance, they are not prepared in accordance with Generally Accepted Accounting Principles (GAAP) and should be viewed alongside official GAAP reporting.

Biogen Idec is providing "pro forma" information to offer investors a clearer and more comparable view of the combined company's operating results and trends. By presenting revenues as if the merger occurred earlier, management aims to facilitate a better understanding of the consolidated entity's revenue generation and future performance potential.

When information is "furnished" under Item 12, as this press release is, it means the company is providing the information to the SEC but is not subject to the same liabilities under Section 18 of the Securities Exchange Act of 1934 as if it were formally "filed". This is a common distinction for certain types of disclosures, like press releases announcing non-GAAP measures.